Balaxi Pharmaceuticals Limited (NSE:BALAXI)

Balaxi Pharmaceuticals Income Statement

Financials in millions INR. Fiscal year is April - March.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021
Operating Revenue	2,757	2,926	2,413	3,364	2,794	2,313
Revenue	2,757	2,926	2,413	3,364	2,794	2,313
Revenue Growth (YoY)	-0.15%	21.25%	-28.28%	20.42%	20.77%	406.95%
Cost of Revenue	1,501	1,659	1,289	2,072	1,980	1,728
Gross Profit	1,256	1,266	1,124	1,293	814.24	585.36
Selling, General & Admin	1,046	894.05	656.74	727.32	312.19	160.86
Other Operating Expenses	-	-	-0.11	-0.26	-0.3	-1.75
Operating Expenses	1,066	912.99	677.62	744.58	317.02	162.45
Operating Income	189.92	353.21	446.44	548.12	497.22	422.9
Interest Expense	-36.5	-29.35	-16.77	-5	-1.42	-0.13
Interest & Investment Income	-	-	-	-	-	0.02
Currency Exchange Gain (Loss)	-60.78	-60.78	-32.79	18.65	49.42	20.5
Other Non Operating Income (Expenses)	42.88	23.61	6.21	7.46	-	-0
EBT Excluding Unusual Items	135.53	286.7	403.09	569.22	545.22	443.29
Other Unusual Items	-	-	-382.93	-	-	-
Pretax Income	135.53	286.7	20.15	569.22	545.22	443.29
Income Tax Expense	41.11	35.99	44.02	109.6	68.65	61.92
Net Income	94.42	250.7	-23.87	459.63	476.58	381.37
Net Income to Common	94.42	250.7	-23.87	459.63	476.58	381.37
Net Income Growth	-65.50%	-	-	-3.56%	24.96%	524.83%
Shares Outstanding (Basic)	54	55	51	50	50	50
Shares Outstanding (Diluted)	54	55	51	51	50	50
Shares Change (YoY)	-0.91%	7.26%	1.69%	1.23%	-	32.96%
EPS (Basic)	1.75	4.54	-0.46	9.16	9.53	7.63
EPS (Diluted)	1.75	4.54	-0.46	9.08	9.53	7.63
EPS Growth	-65.21%	-	-	-4.74%	24.96%	369.94%
Free Cash Flow	-	-561.23	41.74	-69.83	288.23	-12.74
Free Cash Flow Per Share	-	-10.17	0.81	-1.38	5.76	-0.26
Dividend Per Share	-	-	-	-	0.100	-
Gross Margin	45.55%	43.28%	46.58%	38.42%	29.14%	25.30%
Operating Margin	6.89%	12.07%	18.50%	16.29%	17.80%	18.28%
Profit Margin	3.42%	8.57%	-0.99%	13.66%	17.06%	16.49%
Free Cash Flow Margin	-	-19.18%	1.73%	-2.08%	10.32%	-0.55%
EBITDA	204.1	370.3	467.42	565.64	502.34	425.88
EBITDA Margin	7.40%	12.66%	19.37%	16.81%	17.98%	18.41%
D&A For EBITDA	14.18	17.1	20.98	17.53	5.12	2.98
EBIT	189.92	353.21	446.44	548.12	497.22	422.9
EBIT Margin	6.89%	12.07%	18.50%	16.29%	17.80%	18.28%
Effective Tax Rate	30.33%	12.55%	218.44%	19.25%	12.59%	13.97%
Revenue as Reported	2,739	2,888	2,386	3,391	2,844	2,336
Advertising Expenses	-	6.41	6.55	8.41	10.21	1.02

Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.